Tackling the cancer burden: the economic impact of primary prevention policies.


Journal

Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230

Informations de publication

Date de publication:
03 2021
Historique:
received: 18 06 2020
revised: 23 09 2020
accepted: 30 09 2020
pubmed: 7 10 2020
medline: 29 12 2021
entrez: 6 10 2020
Statut: ppublish

Résumé

Cancer is a noncommunicable disease (NCD) with increasing incidence and therefore constitutes a major public health issue. To reduce the health and economic burden of cancer, policy-makers across the world have implemented a range of preventative interventions targeting risk factors with a known link to the disease. In this article, we examine the impact of six primary prevention interventions - related to physical inactivity, unhealthy diet or harmful alcohol use - on cancer-related health outcomes and healthcare expenditure. Here, we used the OECD Strategic Public Health Planning for NCDs (SPHeP-NCDs) model to quantify outcomes and costs for each intervention for years 2020-2050 across 37 countries. Results from the model indicate that all interventions could lead to a reduction in the number of new cancer cases, in particular those targeting harmful alcohol consumption. Introducing an alcohol tax, for instance, is estimated to reduce related cancer cases by 5619 a year or 174 193 by 2050. A breakdown of results by type of cancer revealed interventions had the largest impact on colorectal cancer with, on average, 41 140 cases avoided per intervention by 2050. In proportional terms, interventions had the greatest impact on new oesophageal and liver cancers. Findings from this article are designed to assist decision-makers efficiently allocate limited resources to meet public health objectives.

Identifiants

pubmed: 33021030
doi: 10.1002/1878-0261.12812
pmc: PMC7931126
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

779-789

Informations de copyright

© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

Références

Am J Prev Med. 2001 Jul;21(1):41-7
pubmed: 11418256
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1018-28
pubmed: 27340121
J Natl Cancer Inst. 2015 Sep 30;107(12):djv273
pubmed: 26424777
Obes Rev. 2016 Mar;17(3):201-10
pubmed: 26693944
Br J Cancer. 2018 Apr;118(8):1130-1141
pubmed: 29567982
Eur J Cancer. 2010 Sep;46(14):2605-16
pubmed: 20843489
Gastroenterol Clin North Am. 2009 Mar;38(1):27-57, vii
pubmed: 19327566
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
J Acad Nutr Diet. 2014 Sep;114(9):1375-1388.e15
pubmed: 25037558
BMC Public Health. 2009 Mar 25;9:88
pubmed: 19320986
JAMA Oncol. 2018 Nov 1;4(11):1553-1568
pubmed: 29860482
Can J Public Health. 2019 Feb;110(1):4-14
pubmed: 30238324
MMWR Morb Mortal Wkly Rep. 2017 Oct 03;66(39):1052-1058
pubmed: 28981482
BMJ Open. 2014 Jul 25;4(7):e004787
pubmed: 25063459
Obes Rev. 2016 May;17(5):467-81
pubmed: 26990220
Lancet. 2017 Sep 16;390(10100):1423-1459
pubmed: 28916366
J Cancer Policy. 2018 Dec;18:40-51
pubmed: 30510896
Ann Transl Med. 2017 Apr;5(7):161
pubmed: 28480197
Eur J Cancer Prev. 2015 Mar;24(2):141-9
pubmed: 25089375
Front Med (Lausanne). 2020 Feb 05;6:325
pubmed: 32117999
Lancet. 2010 Nov 20;376(9754):1775-84
pubmed: 21074255
Am J Prev Med. 2016 Feb;50(2):241-8
pubmed: 26470806
BMJ. 2019 Sep 25;366:l5274
pubmed: 31554617
BMC Public Health. 2020 Mar 14;20(1):333
pubmed: 32171267
CA Cancer J Clin. 2018 Nov;68(6):446-470
pubmed: 30303518
J Epidemiol Community Health. 2001 Oct;55(10):755-61
pubmed: 11553661

Auteurs

Jane Cheatley (J)

Health Division, Organization of Economic Cooperation and Development, Paris, France.

Alexandra Aldea (A)

Health Division, Organization of Economic Cooperation and Development, Paris, France.

Aliénor Lerouge (A)

Health Division, Organization of Economic Cooperation and Development, Paris, France.

Marion Devaux (M)

Health Division, Organization of Economic Cooperation and Development, Paris, France.

Sabine Vuik (S)

Health Division, Organization of Economic Cooperation and Development, Paris, France.

Michele Cecchini (M)

Health Division, Organization of Economic Cooperation and Development, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH